# Website Projects Overview

## A1 Diagnosis Website
- **URL**: https://a1diagnosis.com/
- **Alt URL**: https://www.a1diagnosis.com
- **Status**: Under development with comprehensive presentation system
- **Repository**: https://github.com/drozgul/a1diagnosis-website
- **Hosting**: Netlify
- **Current State**: Contains sophisticated medical technology presentation
- **Design**: Clean white layout with professional medical presentation interface

### **A1 Diagnosis Project Overview**
**Business Focus**: AMD (Age-related Macular Degeneration) Blood Test Risk Assessment Platform
- **Market**: $42.3 billion total addressable market
- **Target**: 169 million Americans 35+
- **Innovation**: First blood-based AMD risk assessment test
- **Accuracy**: 94-95% test accuracy rate
- **Business Model**: Inspired by Exact Sciences ($9.9B market cap, $2.76B revenue)

### **Presentation System (3,852 lines of code)**
**Location**: `/presentation/presentation.html`
**Language**: Turkish (TÃ¼rkÃ§e)
**Features**:
- Mobile auto-detection and redirect system
- Interactive sidebar navigation (15 main sections)
- Video integration with synchronized animations
- Chart.js data visualizations
- Custom cursor effects and animations
- Team profiles with individual slide links
- Professional contact system
- Demo AMD risk assessment interface
- Print-friendly responsive design

**Key Presentation Sections**:
1. **ðŸ’¡ YÃ¶netici Ã–zeti** - Executive Summary with video demo
2. **ðŸ’¡ Kritik Problem** - 20M Americans affected by AMD
3. **ðŸ’¡ Ã‡Ä±ÄŸÄ±r AÃ§an Ã‡Ã¶zÃ¼mÃ¼mÃ¼z** - Blood test breakthrough solution
4. **ðŸ’¡ AMD Risk Demo** - Interactive risk assessment report (99.3% high risk demo)
5. **ðŸ’¡ KanÄ±tlanmÄ±ÅŸ Ä°ÅŸ Modeli** - Exact Sciences analysis and success model
6. **ðŸ’¡ Pazar FÄ±rsatÄ±** - Market opportunity with 1% target market share
7. **ðŸ’¡ Finansal Projeksiyonlar** - 5-year growth to $400M revenue
8. **ðŸ’¡ Medicare Geri Ã–deme** - US insurance reimbursement strategy
9. **ðŸ’¡ GeliÅŸtirme AÅŸamalarÄ±** - 3-phase development timeline
10. **ðŸ’¡ AÅŸama 1 DetaylÄ±** - Detailed Phase 1 milestones
11. **ðŸ’¡ YatÄ±rÄ±m Gereksinimleri** - $654,875 Phase 1 funding needs
12. **ðŸ’¡ Ekibimiz** - Team of 8 experts (108+ years experience, $115M+ funding)
13. **ðŸ’¡ YatÄ±rÄ±m GerekÃ§esi** - Investment rationale and advantages
14. **ðŸ’¡ Ä°letiÅŸim** - Professional contact information (Dr. Mustafa Ã–zgÃ¼l)
15. **ðŸ“‹ FDA DÃ¼zenleyici** - FDA De Novo pathway strategy

**Technical Implementation**:
- Responsive design with mobile breakpoints
- Chart.js integration for financial projections
- Video synchronization with process step highlighting
- Custom CSS animations and gradients
- Professional color schemes (teal, blue, green gradients)
- Interactive hover effects and transitions
- Print optimization for PDF export

### **Team & Leadership (8 Key Members)**
**Core Team**:
1. **Dr. Mustafa Ã–zgÃ¼l** - Founder & CEO, UC Irvine AMD Researcher (6 years)
2. **Dr. Murat Baday** - Co-founder, Stanford & Synapses Ventures ($6.1M Series A)
3. **Daniel Chatelain** - Strategic Business Advisor, BayPay Forum Founder (20+ years Fintech)
4. **Prof. Prashanth Asuri** - Health Innovation Advisor, Santa Clara University, Ex-Genentech

**Scientific Advisors**:
5. **Prof. Ramasamy Paulmurugan** - Stanford Professor, $10M+ NIH, 203+ Publications
6. **Danny Seth** - Neurology Diagnostics Expert, Redwood Bio CEO (Alzheimer Blood Test), Harvard MBA + MIT + $5M
7. **Dr. Chirag Patel** - Neuro-Oncology Specialist, MD Anderson Cancer Center, MD/PhD
8. **Prof. Emre Araci** - Technology Advisor, Santa Clara University, Smartlens Inc. Co-founder

**Team Metrics**:
- **Combined Experience**: 108+ years
- **Proven Funding**: $115M+ raised across team
- **Scientific Publications**: 250+
- **Medical Expertise**: AMD research, neurology, oncology, bioengineering
- **Business Success**: Multiple successful exits and Series A/D rounds

### **Business Model & Strategy**
**Revenue Model**: Blood-based diagnostic testing (B2B2C)
- **Inspiration**: Exact Sciences model (Cologuard success story)
- **Distribution**: Family medicine practices â†’ blood test â†’ AI analysis â†’ risk report
- **Pricing**: $250 per test
- **Target Market**: Americans 35+ (169.1 million potential users)
- **Market Entry**: 4.5 million new users annually (turning 35)

**5-Year Financial Projections**:
- **Year 1**: 50K tests, $12.5M revenue (0.02% market share)
- **Year 2**: 200K tests, $50M revenue (0.1% market share)  
- **Year 3**: 500K tests, $125M revenue (0.3% market share)
- **Year 4**: 1M tests, $250M revenue (0.6% market share)
- **Year 5**: 1.6M tests, $400M revenue (1.0% market share)

**Regulatory Strategy**:
- **FDA Pathway**: De Novo classification (Class II with special controls)
- **Timeline**: 150-day FDA review under MDUFA V
- **Precedent**: IDx-DR (2018) - first autonomous AI diagnostic system
- **Compliance**: 21 CFR 862.1840 (mass spectrometry), 21 CFR 886.1100 (retinal software)
- **Quality**: ISO 13485:2016, CLIA laboratory certification required

**Competitive Advantages**:
- **First-to-Market**: No existing blood-based AMD screening tests
- **Preventive Care**: Medicare reimbursement potential (preventive services covered)
- **AI Integration**: Machine learning risk assessment algorithms  
- **Proven Team**: Track record of successful medical device/diagnostic exits
- **Scalable Platform**: Expandable to other retinal diseases (glaucoma, diabetic retinopathy)

### **Development Phases & Investment**
**Phase 1: Pre-Clinical Validation & FDA Consultation (9-24 months)**
- **Investment Required**: $654,875
- **Key Activities**: 
  - 240 blood sample analysis from 3+ centers
  - FDA Q-Sub meeting (De Novo pathway approval)
  - Algorithm validation and accuracy improvement
  - CLIA laboratory partnership establishment
  - Quality Management System (ISO 13485:2016)
- **Deliverables**: Validated algorithm, FDA pathway approval, regulatory strategy

**Phase 2: Clinical Validation & Regulatory Submission (6-24 months)**
- **Multi-center clinical studies** (80% statistical power, 3+ sites)
- **De Novo classification submission** with special control recommendations
- **FDA review process** (150-day timeline under MDUFA V)
- **Post-market surveillance system** setup

**Phase 3: Commercial Launch & Market Penetration (12 months)**
- **CLIA laboratory certification** and commercial partnerships
- **Medicare coverage determination** and private insurance negotiations
- **Healthcare provider education** and market access programs
- **Platform expansion** to additional retinal diseases

### **Presentation Assets (Committed to Repository)**
**Media Files** (30 total files in `/presentation/` folder):
- **Videos**: `A1-English.mov`, `Great Video July 11 2025 - 36 Seconds.mov`
- **Team Photos**: Individual photos for all 8 team members
- **Documents**: Team CVs, advisor profiles, research documents
- **Presentations**: 
  - `presentation.html` (main desktop version - 3,852 lines)
  - `presentation-mobile.html` (mobile optimized)
  - `presentation-mobile-english.html` (English mobile version)
  - Individual team member slides (8 separate HTML files)

**File Status**: âœ… All 29 files committed and pushed to GitHub repository
**Access**: Available at `https://a1diagnosis.com/presentation/presentation.html`

## 01Data Website  
- **URL**: https://01data.org/
- **Alt URL**: https://www.01data.org
- **Status**: Live and functional
- **Repository**: https://github.com/01data01/01data-website
- **Hosting**: Netlify
- **Services**: 
  - Advanced Statistical Analysis
  - Data Visualization
  - Predictive AI/ML Models
  - Research Consulting
  - Custom Analytical Solutions
- **Key Features**:
  - Three.js animated background with floating data visualization elements
  - Google Sign-In authentication system
  - Intelligent Management Platform
  - Personalized user dashboard
  - AI-powered executive intelligence platform
  - Responsive design with custom cursor effects
  - Cookie consent management

## Development Notes
- Both websites are hosted on Netlify
- Different GitHub repositories for each project
- Need to be careful which website we're updating during development

## Local Folder Structure
- **A1 Diagnosis website**: `/Users/mariaolvera/Desktop/A1Diagnosis website/`
- **01data website**: `/Users/mariaolvera/Desktop/01data website/`
- Current working directory: A1 Diagnosis website folder

## CLAUDE.md Files
- **A1 Diagnosis**: This file contains basic website information and development reminders
- **01data**: Comprehensive CLAUDE.md exists in `/Users/mariaolvera/Desktop/01data website/CLAUDE.md` with detailed technical documentation, git history, AI chatbot systems, and project status

## Git Configuration & Credentials
### A1 Diagnosis Website (Current Repository)
- **Git Username**: `drozgul`
- **Git Email**: `aimldrozgul@gmail.com`
- **GitHub Account**: https://github.com/drozgul
- **Repository**: https://github.com/drozgul/a1diagnosis-website
- **Authentication**: Personal access token configured

### 01Data Website 
- **Git Username**: `01data01`
- **Git Email**: `support@01data.org`  
- **GitHub Account**: https://github.com/01data01
- **Repository**: https://github.com/01data01/01data-website
- **Authentication**: Separate credentials required

## Mobile Website Structure (index-mobile.html)
**File Overview**: 2,207 lines total - Mobile-optimized A1 Diagnosis website

**Structure Breakdown**:
1. **HTML Head** (lines 1-1240): Meta tags, mobile optimizations, extensive CSS styling
2. **Navigation** (lines 1243-1269): Mobile-responsive navbar with hamburger menu
3. **Hero Section** (lines 1272-1304): Video background with animated text
4. **Ticker Band** (lines 1306-1324): Scrolling statistics
5. **Vision Protection Video** (lines 1327-1344): Second video section
6. **Vision Cards Section** (lines 1346-1538): Interactive content cards
7. **Problem Section** (lines 1540-1617): AMD statistics and challenges
8. **Solution Section** (lines 1619-1645): Three-step process
9. **Value Proposition** (lines 1647-1676): Key benefits
10. **Benefits Section** (lines 1680-1778): Stakeholder benefits
11. **Path Forward** (lines 1780-1837): Call-to-action sections
12. **Contact/CTA** (lines 1839-1852): Final call-to-action
13. **Footer** (lines 1854-1870): Site navigation links
14. **JavaScript** (lines 1872-2205): Mobile interactions and animations

**Key Mobile Features**:
- Mobile-first responsive design with specific breakpoints
- Touch-optimized buttons and navigation
- Video fallback system (MP4 â†’ GIF â†’ gradient)
- Cinematic text animations synchronized with video
- Mobile menu with hamburger icon
- Scroll-based animations and effects
- Performance optimizations for mobile devices

## Important Reminders
- **CRITICAL**: At the beginning of each conversation, ask which website we're working on and confirm the correct local folder
- Always verify which project we're working on before making changes
- Check repository URLs before pushing changes
- Ensure correct git credentials are configured for each project
- Both sites have different target audiences and functionality requirements
- Confirm local directory matches the intended website before any file operations